2024-03-28T21:00:47Z
https://niigata-u.repo.nii.ac.jp/oai
oai:niigata-u.repo.nii.ac.jp:00022190
2022-12-15T03:52:34Z
453:456
471:537:538:1197
Serological Diagnosis of Hepatocellular Carcinoma(Clinical Application of Tumor Antigen)
3) 肝細胞癌の血清学的診断(シンポジウム 腫瘍抗原の臨床診断への応用, 第452回新潟医学会)
3) 肝細胞癌の血清学的診断(シンポジウム 腫瘍抗原の臨床診断への応用, 第452回新潟医学会)
鈴木, 康史
134893
板谷, 啓司
134894
青柳, 豊
134895
小黒, 仁
134896
横田, 剛
134897
斉藤, 敦
134898
五十嵐, 健太郎
134899
上村, 朝輝
134900
朝倉, 均
134901
Hepatocellular carcinoma (HCC)
Alpha-fetoprotein (AFP)
PIVKA-II
SLX
CA-50
肝細胞癌
アルファフェトプロテイン
異常プロトロンビン
The serum concentration and degree of fucosylation (Fucosylation index) of alpha-fetoprotein (AFP) were determined in serum samples from 322 patients with hepatocellular carcinoma (HCC) and 155 with benign liver diseases (BLD). The serum concentration of PIVKA-II, sialyl SSEA (SLX) and CA-50 were also determined 60 with HCC and 60 with BLD. When the serum AFP concentration was below 1000ng/ml, there was no demarcation line between HCC and BLD. However, the fucosylation index of AFP proved useful to discriminate HCC from patient with an increased concentration of AFP. On the other hand, positive reactions were noted in the following percentage of sera from HCC by PIVKA-II, 53% and SLX, 30%, respectively. It was concluded that the measurement of AFP concentration and of the fucosylation index together with PIVKA-II and SLX enable us to diagnose 88% of patients with HCC, serologically.
departmental bulletin paper
新潟医学会
1990-06
application/pdf
新潟医学会雑誌
6
104
465
470
新潟医学会雑誌
AN00182415
00290440
https://niigata-u.repo.nii.ac.jp/record/22190/files/104(6)_465-470.pdf
jpn